Literature DB >> 25587085

LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a.

Jiaqian Liang1, Yirong Li2, Garrett Daniels2, Karen Sfanos3, Angelo De Marzo3, Jianjun Wei4, Xin Li5, Wenqiang Chen6, Jinhua Wang7, Xuelin Zhong2, Jonathan Melamed2, Jun Zhao8, Peng Lee9.   

Abstract

UNLABELLED: The microRNA-34a (miR-34a), a tumor-suppressive microRNA (miRNA), is implicated in epithelial-mesenchymal transition (EMT) and cancer stem cells. Lymphoid enhancer-binding factor-1 (LEF1) is a key transcription factor in the Wnt signaling pathway, and has been suggested to be involved in regulation of cell proliferation and invasion. Here, the molecular mechanism of miR-34a and LEF1 in cooperatively regulating prostate cancer cell invasion is described. Molecular profiling analysis of miRNA levels in prostate cancer cells revealed a negative correlation between miR-34a and LEF1 expression, and the downregulation of LEF1 by miR-34a was confirmed by luciferase assays. Furthermore, miR-34a specifically repressed LEF1 expression through direct binding to its 3'-untranslated regions (3'-UTR). miR-34a modulated the levels of LEF1 to regulate EMT in prostate cancer cells. Functionally, miR-34a negatively correlated with the migration and invasion of prostate cancer cells through LEF1. An analysis of miR-34a expression levels in matched human tumor and benign tissues demonstrated consistent and statistically significant downregulation of miR-34a in primary prostate cancer specimens. These data strongly suggest that miR-34a/LEF1 regulation of EMT plays an important role in prostate cancer migration and invasion. IMPLICATIONS: The miR-34a-LEF1 axis represents a potential molecular target for novel therapeutic strategies in prostate cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25587085      PMCID: PMC4437214          DOI: 10.1158/1541-7786.MCR-14-0503

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment.

Authors:  Chieh-Yang Cheng; Chang-Il Hwang; David C Corney; Andrea Flesken-Nikitin; Longchang Jiang; Gülfem Meryem Öner; Robert J Munroe; John C Schimenti; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Cell Rep       Date:  2014-03-13       Impact factor: 9.423

2.  Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.

Authors:  Tindara Franchina; Valeria Amodeo; Giuseppe Bronte; Giuseppina Savio; Giuseppina R R Ricciardi; Maria Picciotto; Antonio Russo; Antonio Giordano; Vincenzo Adamo
Journal:  J Cell Physiol       Date:  2014-01       Impact factor: 6.384

3.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

4.  A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells.

Authors:  Pengcheng Bu; Kai-Yuan Chen; Joyce Huan Chen; Lihua Wang; Jewell Walters; Yong Jun Shin; Julian P Goerger; Jian Sun; Mavee Witherspoon; Nikolai Rakhilin; Jiahe Li; Herman Yang; Jeff Milsom; Sang Lee; Warren Zipfel; Moonsoo M Jin; Zeynep H Gümüş; Steven M Lipkin; Xiling Shen
Journal:  Cell Stem Cell       Date:  2013-05-02       Impact factor: 24.633

5.  Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition.

Authors:  Shumin Zhang; Xu Wang; Shareen Iqbal; Yanru Wang; Adeboye O Osunkoya; Zhengjia Chen; Zhuo Chen; Dong M Shin; Hongwei Yuan; Yongqiang A Wang; Haiyen E Zhau; Leland W K Chung; Chad Ritenour; Omer Kucuk; Daqing Wu
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

6.  Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer.

Authors:  Helge Siemens; Jens Neumann; Rene Jackstadt; Ulrich Mansmann; David Horst; Thomas Kirchner; Heiko Hermeking
Journal:  Clin Cancer Res       Date:  2012-12-14       Impact factor: 12.531

7.  The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.

Authors:  T Ezponda; R Popovic; M Y Shah; E Martinez-Garcia; Y Zheng; D-J Min; C Will; A Neri; N L Kelleher; J Yu; J D Licht
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

8.  Genome-wide identification and comparative analysis of conserved and novel microRNAs in grafted watermelon by high-throughput sequencing.

Authors:  Na Liu; Jinghua Yang; Shaogui Guo; Yong Xu; Mingfang Zhang
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

9.  Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway.

Authors:  Weiming Duan; Yaxiang Xu; Yujin Dong; Lili Cao; Jian Tong; Xinwen Zhou
Journal:  J Radiat Res       Date:  2013-01-24       Impact factor: 2.724

10.  IGF2BP1 promotes mesenchymal cell properties and migration of tumor-derived cells by enhancing the expression of LEF1 and SNAI2 (SLUG).

Authors:  Anne Zirkel; Marcell Lederer; Nadine Stöhr; Nikolaos Pazaitis; Stefan Hüttelmaier
Journal:  Nucleic Acids Res       Date:  2013-05-15       Impact factor: 16.971

View more
  34 in total

Review 1.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

2.  Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.

Authors:  Di Wen; Yang Peng; Feng Lin; Rakesh K Singh; Ram I Mahato
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

3.  Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.

Authors:  Xiao-Fei Song; Qi-Hua Wang; Ran Huo
Journal:  Pathol Oncol Res       Date:  2017-11-14       Impact factor: 3.201

Review 4.  Message in hand: the application of CRISPRi, RNAi, and LncRNA in adenocarcinoma.

Authors:  Ting Wang; Yunhong Yao; Xinrong Hu; Yi Zhao
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

Review 5.  The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Authors:  Linda Fabris; Yvonne Ceder; Arul M Chinnaiyan; Guido W Jenster; Karina D Sorensen; Scott Tomlins; Tapio Visakorpi; George A Calin
Journal:  Eur Urol       Date:  2016-01-22       Impact factor: 20.096

Review 6.  Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.

Authors:  Larion Santiago; Garrett Daniels; Dongwen Wang; Fang-Ming Deng; Peng Lee
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 7.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

8.  Familial adenomatous patients with desmoid tumours show increased expression of miR-34a in serum and high levels in tumours.

Authors:  Sarah-Jane Walton; Amy Lewis; Rosemary Jeffery; Hannah Thompson; Roger Feakins; Eleni Giannoulatou; Christopher Yau; James O Lindsay; Susan K Clark; Andrew Silver
Journal:  Oncoscience       Date:  2016-06-30

Review 9.  Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.

Authors:  Alessandra Bosutti; Fabrizio Zanconati; Gabriele Grassi; Barbara Dapas; Sabina Passamonti; Bruna Scaggiante
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

Review 10.  Wnt-signalling pathways and microRNAs network in carcinogenesis: experimental and bioinformatics approaches.

Authors:  Emenike K Onyido; Eloise Sweeney; Abdolrahman Shams Nateri
Journal:  Mol Cancer       Date:  2016-09-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.